In 31 adult transplant recipients (30 solid organ) with norovirus, nitazoxanide did not shorten median time to symptom resolution vs placebo (19.0 vs 11.0 days; P=.459) or time to negative stool PCR; no serious drug-related adverse events.
RCTn = 31
Boutin et al. A phase 2 multicenter, prospective, randomized, double-blind study to assess the clinical and antiviral efficacy and safety of nitazoxanide for the treatment of norovirus in hematopoietic stem cell and solid organ transplant recipients